Proair Digihaler is an inhalation drug owned by Teva Branded Pharm. Its active ingredient is albuterol sulfate and was authorized for market use on 31 March, 2015. It is available in powder, metered; inhalation dosage forms. Proair Digihaler has a total of 22 drug patents out of which 1 drug patent has expired.
The generics of Proair Digihaler could possibly be released after 22 February, 2041. This is concluded after considering the expiry dates of its current active patents.
Proair Digihaler is used for treating respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). albuterol sulfate, the active ingredient, works by relaxing and opening air passages to the lungs, making it easier to breathe.
Proair Digihaler has a total of 22 patents. The last patent (US11266796) with the title 'Inhalation device with integrated electronics' is due to expire on 22 February, 2041. Due to this, it's estimated that Proair Digihaler generic could be available after this date. Below are the patent details: